company background image
IVX

Invion ASX:IVX Stock Report

Last Price

AU$0.012

Market Cap

AU$77.0m

7D

-7.7%

1Y

-14.3%

Updated

28 Sep, 2022

Data

Company Financials
IVX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

IVX Stock Overview

Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia.

Invion Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Invion
Historical stock prices
Current Share PriceAU$0.012
52 Week HighAU$0.034
52 Week LowAU$0.008
Beta2.37
1 Month Change20.00%
3 Month Change33.33%
1 Year Change-14.29%
3 Year Change-14.29%
5 Year Change200.00%
Change since IPO-96.96%

Recent News & Updates

Aug 16
We're Not Very Worried About Invion's (ASX:IVX) Cash Burn Rate

We're Not Very Worried About Invion's (ASX:IVX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Shareholder Returns

IVXAU PharmaceuticalsAU Market
7D-7.7%-4.6%-3.3%
1Y-14.3%-25.2%-10.6%

Return vs Industry: IVX exceeded the Australian Pharmaceuticals industry which returned -25.2% over the past year.

Return vs Market: IVX underperformed the Australian Market which returned -10.6% over the past year.

Price Volatility

Is IVX's price volatile compared to industry and market?
IVX volatility
IVX Average Weekly Movement16.2%
Pharmaceuticals Industry Average Movement10.9%
Market Average Movement9.6%
10% most volatile stocks in AU Market16.7%
10% least volatile stocks in AU Market4.3%

Stable Share Price: IVX is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: IVX's weekly volatility has decreased from 24% to 16% over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2000n/aThian Chewhttps://www.inviongroup.com

Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion’s IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer.

Invion Fundamentals Summary

How do Invion's earnings and revenue compare to its market cap?
IVX fundamental statistics
Market CapAU$77.04m
Earnings (TTM)-AU$2.24m
Revenue (TTM)AU$3.29m

23.5x

P/S Ratio

-35.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IVX income statement (TTM)
RevenueAU$3.29m
Cost of RevenueAU$2.32m
Gross ProfitAU$969.12k
Other ExpensesAU$3.21m
Earnings-AU$2.24m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.00034
Gross Margin29.44%
Net Profit Margin-68.09%
Debt/Equity Ratio0.0%

How did IVX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is IVX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IVX?

Other financial metrics that can be useful for relative valuation.

IVX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue20.8x
Enterprise Value/EBITDA-37.7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does IVX's PS Ratio compare to its peers?

IVX PS Ratio vs Peers
The above table shows the PS ratio for IVX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average18.9x
EOF Ecofibre
2.6xn/aAU$78.8m
BOT Botanix Pharmaceuticals
24.5xn/aAU$67.3m
LGP Little Green Pharma
5.7xn/aAU$60.2m
FRE Firebrick Pharma
43xn/aAU$46.5m
IVX Invion
23.5xn/aAU$77.0m

Price-To-Sales vs Peers: IVX is expensive based on its Price-To-Sales Ratio (23.5x) compared to the peer average (18.9x).


Price to Earnings Ratio vs Industry

How does IVX's PE Ratio compare vs other companies in the AU Pharmaceuticals Industry?

Price-To-Sales vs Industry: IVX is expensive based on its Price-To-Sales Ratio (23.5x) compared to the Australian Pharmaceuticals industry average (9.1x)


Price to Sales Ratio vs Fair Ratio

What is IVX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IVX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio23.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate IVX's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of IVX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IVX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IVX's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Invion forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


40.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Invion has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine Invion's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • Invion competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Invion performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


22.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IVX is currently unprofitable.

Growing Profit Margin: IVX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IVX is unprofitable, but has reduced losses over the past 5 years at a rate of 22.4% per year.

Accelerating Growth: Unable to compare IVX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IVX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.1%).


Return on Equity

High ROE: IVX has a negative Return on Equity (-11.45%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Invion's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: IVX's short term assets (A$8.6M) exceed its short term liabilities (A$462.4K).

Long Term Liabilities: IVX has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: IVX is debt free.

Reducing Debt: IVX has no debt compared to 5 years ago when its debt to equity ratio was 31%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IVX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IVX has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 16.9% each year.


Discover healthy companies

Dividend

What is Invion current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Invion Dividend Yield vs Market
How does Invion dividend yield compare to the market?
SegmentDividend Yield
Company (Invion)n/a
Market Bottom 25% (AU)2.8%
Market Top 25% (AU)7.2%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast in 3 Years (Invion)n/a

Notable Dividend: Unable to evaluate IVX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IVX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IVX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IVX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IVX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Thian Chew

4.75yrs

Tenure

AU$1,502,764

Compensation

Mr. Thian Chew has been Executive Chairman and Chief Executive Officer at Invion Limited since November 1, 2020 and also served as Interim Chief Executive Officer since October 31, 2020 until November 1, 2...


CEO Compensation Analysis

Thian Chew's Compensation vs Invion Earnings
How has Thian Chew's remuneration changed compared to Invion's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022AU$2mAU$309k

-AU$2m

Mar 31 2022n/an/a

-AU$2m

Dec 31 2021n/an/a

-AU$2m

Sep 30 2021n/an/a

-AU$2m

Jun 30 2021AU$368kAU$266k

-AU$1m

Mar 31 2021n/an/a

-AU$1m

Dec 31 2020n/an/a

-AU$625k

Sep 30 2020n/an/a

-AU$790k

Jun 30 2020AU$194kn/a

-AU$954k

Dec 31 2019n/an/a

-AU$2m

Sep 30 2019n/an/a

-AU$2m

Jun 30 2019AU$138kn/a

-AU$3m

Dec 31 2018n/an/a

-AU$1m

Sep 30 2018n/an/a

-AU$1m

Jun 30 2018AU$53kn/a

-AU$927k

Compensation vs Market: Thian's total compensation ($USD968.21K) is above average for companies of similar size in the Australian market ($USD274.98K).

Compensation vs Earnings: Thian's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: IVX's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: IVX's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

ASX:IVX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
04 Oct 21SellAU$14,000Robert MerrielIndividual1,000,000AU$0.014

Ownership Breakdown

What is the ownership structure of IVX?
Owner TypeNumber of SharesOwnership Percentage
Private Companies1,329,484,62520.7%
Individual Insiders1,742,777,39227.1%
General Public3,347,830,06452.1%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.9%.


Top Shareholders

Top 19 shareholders own 47.85% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.52%
Thian Chew
546,857,721A$6.6m0%no data
8.49%
Ngpdt Greater China Limited
545,217,721A$6.5m0.01%no data
5.01%
Rmw Cho Group Limited
321,428,571A$3.9m0%no data
4.43%
Honsue Cho
284,626,482A$3.4m-43.67%no data
3.8%
Acslnc Pty Ltd
244,140,000A$2.9m0%no data
3.12%
Chen Yong
200,000,000A$2.4m0%no data
2.12%
Wang Shengli
136,288,074A$1.6m0%no data
1.63%
Dandan Wang
104,476,192A$1.3m0%no data
1.54%
Kit Hui Ming
98,576,667A$1.2m0%no data
1.46%
Rmwc Pty Ltd
93,865,000A$1.1m0%no data
1.24%
Shengwei Ou
79,304,171A$951.7k0%no data
1.14%
Shubo Miao
73,333,333A$880.0k0%no data
1.14%
Graeme Scott
73,000,000A$876.0k0%no data
0.97%
Eq Investment Pty Ltd
62,500,000A$750.0k0%no data
0.97%
Platinum Homes Limited
62,333,333A$748.0k0%no data
0.92%
Ma Yinghua
59,000,000A$708.0k0%no data
0.53%
Esmond Wong
33,782,383A$405.4k0%no data
0.53%
Quynh Nguyen
33,782,382A$405.4k0%no data
0.31%
Alistair Bennallack
19,749,987A$237.0k22.13%no data

Company Information

Invion Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Invion Limited
  • Ticker: IVX
  • Exchange: ASX
  • Founded: 2000
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: AU$77.041m
  • Shares outstanding: 6.42b
  • Website: https://www.inviongroup.com

Number of Employees


Location

  • Invion Limited
  • 100 Albert Road
  • Level 4
  • Melbourne
  • Victoria
  • 3205
  • Australia


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
7C8DB (Deutsche Boerse AG)YesOrdinary SharesDEEURFeb 2010
IVIX.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDFeb 2010
IVXASX (Australian Securities Exchange)YesOrdinary SharesAUAUDFeb 2010
IVXCHIA (Chi-X Australia)YesOrdinary SharesAUAUDFeb 2010

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/28 00:00
End of Day Share Price2022/09/28 00:00
Earnings2022/06/30
Annual Earnings2022/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.